UrologyTUBE

Juan Reyna, MD - BIO

Juan Reyna MD
President emeritus at Urology San Antonio PA
San Antonio, Texas USA

 

juan-reyna-md revJuan A. Reyna, MD is a practicing urologist and the founder and president emeritus of Urology San Antonio, one of the largest urology groups in the United States. In addition, he is president elect for LUGPA, the Large Urology Group Practice Association, a national organization representing the interests nearly 2100 urologists in 120 large group practices across the country.

Dr. Reyna graduated from the University of Texas at Austin where he received his bachelor’s degree in pharmacy. He went on to earn his medical degree from the UT Health Science Center at San Antonio and completed his surgical internship at Baylor College of Medicine in Houston. He returned to his hometown, San Antonio for his urologic residency at the UT Health Science Center, where he was the first Mexican American to complete the program.

In 1981, Dr. Reyna opened his urology practice as a solo practitioner in downtown San Antonio. Through recruitment and mergers, he grew the practice to include 30 urologists, a radiation oncologist and approximately 200 employees. Dr. Reyna served as the group’s president and CEO for 30 years before stepping down in May of 2012. Today, as president emeritus, he provides counsel and support for the business functions of the practice, and has taken it upon himself to be the ambassador and champion of the practices outreach and community-focused initiatives.

Giving others opportunities for success is a driving value for Dr. Reyna. He is a founding member of the Mexican American Hispanic Physician Association (MAHPA), a organization that empowers minority students to pursue careers in health care. He has served on numerous boards for businesses, hospitals and professional associations in San Antonio and at the national level.

In November of 2012, Urology San Antonio, in recognition of Dr. Reyna’s 31 years of service moved to change the name of their cancer center from the San Antonio Cancer Center to The Dr. Johnny Reyna Center for Cancer Treatment.

On Novemer 9, 2013, Dr. Reyna was installed as president of LUGPA-Intrgrated Practices, Comprehensive Care. This is a national organization of over 120 urology groups representing over 2,000 urologists from throughout the United States.

Specialties:
general urology
practice consolidation
surgical specialty administration

 

 

Urology Tube Home

[yee_row column-size="md-column" boxed_layout="yee-container-fluid" padding_layout="" style_detail="" theme_options="flattern" border_color="" border="none" background_image_options="none" background_image="" background_color_options="none" background_color="" responsive_column_reset="no" vacolumns="top" ex_class="" id="" visiable="1"][yee_column width="1/1" ors="" column-size="md-column" xs-column="0" xs-hidden="" sm-column="0" sm-hidden="" md-column="0" md-hidden="" lg-column="0" lg-hidden="" hidden-print="visiable" background_image="" background_color="" ex_class="" visiable="1"][wgt_jce_editor css_animation="no" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"]{content} {/content}[/wgt_jce_editor][/yee_column][/yee_row][yee_row column-size="md-column" boxed_layout="yee-container-fluid" padding_layout="" style_detail="" theme_options="flattern" border_color="" border="none" background_image_options="none" background_image="" background_color_options="none" background_color="" responsive_column_reset="no" vacolumns="top" ex_class="" id="" visiable="1"][yee_column width="1/1" ors="" column-size="md-column" xs-column="0" xs-hidden="" sm-column="0" sm-hidden="" md-column="0" md-hidden="" lg-column="0" lg-hidden="" hidden-print="visiable" background_image="" background_color="" ex_class="" visiable="1"][yee_additional_css ex_class="" visiable="1"]{css_code}.hwd-container .media-details-view .media-item {width: 40%; float: left; padding-right: 10px;} .hwd-container .media-details-view h2.contentheading {font-size: 1em; font-weight: normal; line-height: 1.4em !important; border-bottom: none;} a.yee-btn.yee-btn-lg.yee-btn-block.yee-btn-primary {color: white !important;} .yee-module-title h3 {font-weight: normal; font-size: 1.4em; border-bottom: 3px solid #EFEFEF;} div.yee-widget.yee-wgt-joomla-module-keancorner div.media-item {width: 120px;} div.yee-widget.yee-wgt-joomla-module-keancorner h2.contentheading {width: 260px;} .hwd-container div.media-item img.media-thumb {margin-top: 40px;} .hwd-container .media-details-view .media-item {height: 90px;} .slick-prev::before {content: none;} .hwd-container .slick-prev {background-image: url("/images/leftarrow.png");{/css_code}[/yee_additional_css][yee_button title="Clinical practice InSlides™" href="/" color="yee-btn-primary" size="yee-btn-lg yee-btn-block" state="" icon="fa fa-video-camera" icon_assign="left" target="_self" rel="" ex_class="HomePageTitle" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"][/yee_button][yee_module module="908" show_module_title="show" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"][/yee_module][yee_module module="910" show_module_title="show" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"][/yee_module][yee_module module="912" show_module_title="show" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"][/yee_module][yee_module module="913" show_module_title="show" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"][/yee_module][yee_module module="914" show_module_title="show" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"][/yee_module][yee_module module="915" show_module_title="show" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="0"][/yee_module][yee_module module="916" show_module_title="show" ex_class="-keancorner" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"][/yee_module][/yee_column][/yee_row][yee_row column-size="md-column" boxed_layout="yee-container-fluid" padding_layout="" style_detail="" theme_options="flattern" border_color="" border="none" background_image_options="none" background_image="" background_color_options="none" background_color="" responsive_column_reset="no" vacolumns="top" ex_class="" id="" visiable="1"][yee_column width="1/1" ors="" column-size="md-column" xs-column="0" xs-hidden="" sm-column="0" sm-hidden="" md-column="0" md-hidden="" lg-column="0" lg-hidden="" hidden-print="visiable" background_image="" background_color="" ex_class="" visiable="1"][wgt_jce_editor css_animation="no" ex_class="" style_detail="" yee-widget-theme="default" border_color="" border="none" visiable="1"]{content} {/content}[/wgt_jce_editor][/yee_column][/yee_row]

Dr. Adam S. Kibel - BIO

Kibel Adam MD HRAdam S. Kibel, MD
Chief of Urology
Brigham and Women's Hospital
Chief of Urologic Surgery
Dana-Farber Cancer Institute
Professor of Surgery
Harvard Medical School
Boston, Massachusetts

Adam S. Kibel, MD is Chief of Urology at the Brigham and Women's Hospital and Chief of Urologic Surgery at the Dana-Farber Cancer Institute in Boston, MA. He is also Professor of Surgery at Harvard University School of Medicine. Dr. Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency in the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland.

Dr. Kibel's current research areas focus on the identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches to treatment of aggressive disease, and improved imaging of patients with urologic malignancies. His research has been supported by the NCI, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.

Dr Kibel currently serves on the Executive Committee for the CALGB, the NCI GU Clinical trials steering committee, the SUO Board of Directors, the ASCO-GU program steering committee, and the NCCN Prostate Cancer Screening Committee.

 

Dr. Thompson Jr. - BIO

ian thompson-picDr. Ian Thompson received his undergraduate degree from West Point and his M.D. degree from Tulane University. After a Residency in Urology at Brooke Army Medical Center in San Antonio, he completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He is Director of the Cancer Therapy and Research Center at UTHSCSA, a NCI-designated Cancer Center. Dr. Thompson has published over 500 scientific papers, several dozen book chapters, and has edited six textbooks in medicine and surgery. He serves as Chair of the Early Detection Research Network of the National Cancer Institute and Chairs the Genitourinary Committee of the Southwest Oncology Group.

He has previously chaired the Urology Residency Review Committee of ACGME and is a Trustee of the American Board of Urology. Dr. Thompson is the Principal Investigator of the San Antonio Center for Biomarkers Of Risk of Prostate Cancer. This cohort study, with up to 13 years of followup, follows over 4,000 men for development of prostate cancer. He is the Principal Investigator of the Program Project Grant, The Biology of the PCPT. He was the primary coordinator of the Prostate Cancer Prevention Trial, PI of S8794 (Adjuvant Radiotherapy for pT3 Prostate Cancer), and co-PI of the Selenium and Vitamin E Prevention Trial. Dr. Thompson retired as a Colonel from the U.S. Army, having served as Chair of the Department of Surgery at Brooke Army Medical Center and served in Saudi Arabia and Iraq as a General Surgeon with the 41st Combat Support Hospital during Operation Desert Storm/Shield.

Tomasz M. Beer, MD - Bio

Tom BeerTomasz M. Beer, MD completed his medical training at The Johns Hopkins University School of Medicine in 1991 and went on to complete residency training in internal medicine and fellowship training in Hematology and Medical Oncology at Oregon Health & Science University. Dr. Beer serves as the Grover C. Bagby Endowed Chair for Prostate Cancer Research, Professor of Medicine in the Division of Hematology & Medical Oncology and Deputy Director at the Oregon Health and Science University (OHSU), Knight Cancer Institute in Portland. Dr. Beer serves as a leader of the Prostate Cancer Program of the OHSU Knight Cancer Institute and NCI-designated Cancer Center. Dr. Beer has authored and co-authored more than 250 articles and abstracts on prostate cancer. His major research interests include clinical trials, preclinical investigation and risk factors in prostate cancer. Dr. Beer has been involved in more than 100 clinical trials and has led studies that tested new drugs in humans for the first time as well as large global studies that challenge the current standard of care. In addition to developing, carrying out and leading clinical trials, Dr. Beer is strongly interested in bringing knowledge about cancer clinical trials to people living with cancer. During the past year, Dr. Beer teamed up with Larry Axmaker, a cancer survivor and clinical trial participant to author a book entitled Cancer Clinical Trials, A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials. The authors' blog is at www.cancer-clinical-trials.com.

James L. Gulley, MD, PhD, FACP - BIO

 

gulley headshotJames L. Gulley, MD, PhD, FACP
Chief, Genitourinary Malignancies Branch at National Cancer Institute (NCI)

Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program he completed a dissertation on tumor immunology. He completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI. Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as principal investigator or an associate investigator on approximately 60 trials.

Dr. Gulley is especially interested in immunotherapy for prostate cancer. As Director of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology, he takes promising laboratory findings and uses them to design and conduct clinical trials. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents to modulate the immune response in cancer patients, and the addition of other strategies to enhance vaccine-mediated killing. In particular, he played a pivotal role in the clinical development of a prostate cancer vaccine, created in the National Cancer Institute, and serves as the principal Investigator on a global Phase III randomized clinical trial (Prospect) of this vaccine.

He is also a senior investigator within the Medical Oncology Branch at the National Cancer Institute. Dr. Gulley has received numerous awards including the 2010 Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the US government on outstanding scientists early in their careers. He serves on many boards and committees. He has authored approximately 160 scientific papers and book chapters, edited 4 books and has made numerous invited presentations at national and international meetings.

 

Leonard G. Gomella, MD, FACS - BIO

leonard gomellaThe Bernard W. Godwin Jr. Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director of Clinical Affairs, Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA

Dr. Leonard Gomella is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at Jefferson Medical College. Originally from New York, Dr. Gomella completed medical school, general surgery and urology training at the University of Kentucky in Lexington, Kentucky. After a Urologic Oncology Fellowship in the Surgery Branch of the National Cancer Institute in Bethesda, Maryland he joined the faculty of Jefferson Medical College in 1988 and was appointed Chair in 2002.

Dr. Gomella is involved in both basic science and clinical research in the development of new diagnostic techniques and treatments for prostate, bladder and kidney cancer through Jefferson's Kimmel Cancer Center. Dr. Gomella's team was first to use RT-PCR to detect micrometastasis in patients with prostate cancer, a finding that led to a new field of investigation in this disease. He serves as Associate Director of Clinical Affairs for Kimmel Cancer at Jefferson and Urology Chair for RTOG. Dr. Gomella is also recognized as a contributor to urologic laparoscopy, initiating the program at Jefferson in 1990.

He has given over 400 presentations at local, national and international meetings, written over 250 papers, book chapters and monographs in the field of Urology. Journal appointments have included serving as member of the Editorial Board of the Investigative Section of the "Journal of Urology", as co-editor in chief of "Techniques in Urology", the board of "Urologic Oncology", and "Journal of Laparoendoscopic Surgery". He is a consultant to numerous journals in the field of urology and oncology and is Associate Editor of the "Canadian Journal of Urology".

Dr. Gomella has authored and edited over forty books for medical students, house officers, and practicing physicians, many of which have been translated into foreign languages. He is the editor of the "5 Minute Urology Consult" and co-editor of "Laparoscopic Urologic Surgery", the field's first color atlas. Currently he is the laparoscopy editor for "Glenn's Urologic Surgery". "Recovering From Prostate Cancer" was the first book for the public dedicated to this topic. In the field of medicine, Dr. Gomella is known for the "Clinician's Pocket Reference", now in its 11th edition. It is a widely used reference for medical students and health care providers. He is the series editor for McGraw-Hill's "On Call" resident series. "Best Doctors in America","Top Doctors for Cancer", Philadelphia Magazine's "Top Doctors" have recognized him for many years for urologic oncology and prostate cancer. In 2007, Men's Health Magazine listed him as one of the 20 top urologists in the US. He has been the recipient of many awards including a Pennsylvania Chapter of the American Cancer Society "Volunteer Achievement Award" and a "National Cancer Institute Achievement Award". In 2005-2006, he served as President of the Mid-Atlantic Section of the AUA.

Charles G. Drake, MD, PhD - BIO

 

chuck drakeCharles G. Drake, MD, PhD
Associate Professor, Oncology, Immunology and Urology
Johns Hopkins University School of Medicine
Baltimore, MD USA

Charles Drake received his PhD in Immunology from the National Jewish Center for Immunology and his MD from the University of Colorado Health Sciences Center. After completing an internal medicine residency on the Osler medicine service at Johns Hopkins, he entered the field of medical oncology. During Dr. Drake's oncology fellowship, he began to investigate the immune response to prostate cancer, developing a unique murine model to perform studies on antigen-specific T-cell tolerance to tumors. Experiments in this model supported the concept that androgen-ablation could mitigate tolerance to prostate cancer, creating a window during which tumor vaccination could prove successful (Cancer Cell 2005).

Currently, Dr. Drake is the co-director of the Multidisciplinary Prostate Cancer Clinic at Hopkins, where the combination of androgen-ablation and vaccination is being examined in a translational, pre-surgical trial. Using additional in vivo models, the Drake laboratory showed that LAG-3 is relatively over-expressed on non-functional T cells, and that LAG-3 blockade affects T-cell function in both Treg-dependent and Treg-independent mechanisms (JCI 2007). More recently, the laboratory was able to show that blocking the immune checkpoints PD-1 and LAG-3 could prove synergistic, in several in vivo cancer models. Ongoing work in the laboratory is focused on understanding the role of LAG-3 in regulatory T-cell induction, as well as the regulation of immune checkpoint molecules and ligands in prostate and kidney cancer.

 

Christopher Pieczonka, MD - BIO

PieczonkapngChristopher Pieczonka, MD graduated from the SUNY Buffalo School of Medicine in 1997. He then completed his surgical and urologic training at SUNY at Buffalo Consortium Program in 2003. He is board certified by the American Board of Urology and is an active member of the American Urological Association. Dr. Pieczonka also has been co-author of publications in the Journal of Urology.

Dr. Pieczonka is currently the executive vice-president of the Physician Teamster Alliance of CNY Local #1149 and has a specialty interest in the treatment of advanced prostate cancer. His patients were the first to be treated with Provenge® (sipuleucel-T), a new immunotherapy for metastatic prostate cancer.

E. David Crawford, MD - BIO

crawfordE. David Crawford is an internationally recognized urologist and is the distinguished endowed professor of surgery, urology, and radiation oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. He also serves as the practice director for the urologic oncology clinic. His areas of expertise include benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer.

Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship, at the University of California Medical Center, in Los Angeles.

The recipient of more than 95 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 450 articles that have been published in such journals as Urology, the New England Journal of Medicine, the Journal of Urology, and the Journal of the National Cancer Institute. He has published five textbooks and authored over 50 book chapters, and is an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, the New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology.

Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science. He served as the Chairman of the Genitourinary Cancer Committee of the Southwest Oncology Group for 28 years. He is also the Founder and Chairman of the Prostate Conditions Education Council which is responsible for screening nearly four million men for prostate health issues and reaches more than 200 million people each year with education and awareness information. Dr. Crawford's involvement in the national prostate cancer arena has been widely recognized and he has received many honors and awards, including the CaP Cure Annual Award for Scientific Presentation in 1999. In 1997, he was presented with a “Freddie Award” at the AMA International Health and Medical Film Competition for the program ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Dr. Crawford hosted with special guest retired General Norman Schwarzkopf. He, again, won a prestigious “Freddie Award” in 2005. He has been recognized as one of the Best Doctors of America for the past decade, and Best Cancer Doctors. Recently, he was awarded the honor of being selected as the Best Healthcare Provider in the Denver Metro area by the Denver Business Journal, Blue Cross, and Anthem Healthcare. He is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine.

Bryan Mehlhaff, MD - BIO

Mehlhaff ppAn award-winning scholar and medical student while training at New York's Albany Medical Center Hospital, Dr. Mehlhaff has maintained his drive for excellence throughout his career. He honed his skills in adult and pediatric urology, endourology, and minimally invasive surgery as an assistant urology professor before entering private practice at Oregon Urology Institute. Dr. Mehlhaff continues to be at the forefront of education by serving on a urologic medical advisory board.

Diane K. Newman, DNP, FAAN, BCB-PMD - BIO

newmanDiane K. Newman, DNP, FAAN, BCB-PMD, is Research Investigator Senior at the Perelman School of Medicine, University of Pennsylvania. She is Co-Director of the Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Medical Center, in Philadelphia.

Dr. Newman received a Doctor of Nursing Practice program from Thomas Jefferson University, a Bachelor of Science degree in nursing from LaSalle University, and a Master of Science degree in nursing from the University of Pennsylvania, all in Philadelphia. She is certified as an adult nurse practitioner by the American Nurses Credentialing Center and is a Fellow of the American Academy of Nursing.

Leslie Saltzstein Wooldridge, GNP-BC, CUNP, AGS-F, BCIA-PMBD - BIO

 

wooldridgeLeslie Saltzstein Wooldridge, GNP-BC, CUNP, AGS-F, BCIA-PMBD is a Geriatric Nurse Practitioner, Director of the Mercy Health Partners Bladder Control Center, in Muskegon, Michigan and owner of Diversified Nurse Consulting, LTd. She has over 29 years of experience as an advanced practice nurse. Geriatrics and Urology has been her specialty for the past 23 years.

Ms. Wooldridge received a Master of Science degree in nursing administration, and critical care nursing and a postgraduate certification as a Geriatric Nurse Practitioner from Marquette University in Milwaukee, Wisconsin. Leslie is also certified Urologic Nurse Practitioner as well as certified in pelvic floor muscle biofeedback. She is the 2009 National Association for Continence Rodney J. Appell Continence Champion award recipient.

 

Scott A. MacDiarmid, MD - BIO

macdiarmidScott A. MacDiarmid, MD is director of the Alliance Urology Specialists Bladder Control and Pelvic Pain Center in Greensboro, NC. He completed fellowships in reconstructive urology and urodynamics at Duke University Medical Center in Durham, NC, the University of Otago in Christchurch, New Zealand, and the University of Sheffield in England.

William R. Jarvis, MD - BIO

jarvisWilliam R. Jarvis, MD completed his internship in pediatrics at the University of Texas, Houston. He completed his residency in pediatrics at the Children's Hospital of Los Angeles. He had a Pediatric Infectious Disease Fellowship at the Hospital for Sick Children in Toronto, and at Yale University School of Medicine (virology and public health). He completed his Preventive Medicine Residency at CDC.

He is a Fellow of the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiologists of America (SHEA). He graduated from college with high honors. Dr. Jarvis is a two-time recipient of the Spark's award for academic excellence, has over 20 PHS awards, received the CDC Philip Brachman (teaching) Award, the CDC Lifetime Achievement Award (2003), the CDC Lifetime Achievement Award in Epidemiology (2010), the SHEA Lectureship, and APIC State of the Science Scientific Excellence awards.

Dr. Manoj Monga - BIO

 

mongaDr. Manoj Monga joined Cleveland Clinic's staff in 2010 as Director of the Stevan B. Streem Center for Endourology & Stone Disease. Prior to coming to Cleveland, he was the Joseph Sorkness Family Endowed Professor and Vice-Chair of Urologic Surgery and Director of Endourology & Stone Disease at the University of Minnesota.

Dr. Monga is recognized as an international authority in endourology and stone disease, and has been an invited speaker in India, Thailand, Brazil, Italy, Greece, Mexico, China, United Kingdom and the Netherlands. He has also acted as a Visiting Professor at many of the major medical centers in the United States.

 

Dr. Deepak A. Kapoor - BIO

Deepak KapoorDr. Deepak A. Kapoor, Chairman and Chief Executive Officer of Integrated Medical Professionals (IMP) headquartered in Melville, NY, is one of the youngest physicians to have been certified by the American Board of Urology and comes to IMP with over 20 years of clinical and business expertise. His medical background is diverse with both laboratory and clinical experience, both in the academic and private sectors. Dr. Kapoor´s expertise includes basic science research in molecular biology as well as extensive experience in oncologic and reconstructive surgery.

Under his leadership, Dr. Kapoor’s organization, Integrated Medical Professionals (IMP) has become the largest comprehensive urology group practice in the United States, and is regarded as a national leader in the areas of quality management, utilization review, compliance and the development of coordinated clinical pathways.

In addition to his duties with IMP, Dr. Kapoor is President of the Large Urology Group Practice Association (representing nearly 25% of all practicing urologists in the United States), is Chairman of SCRUBS RRG (the only national urology specific medical malpractice carrier), is a member of the Board of Directors of UroPAC (the national political action committee representing the interests of the specialty of urology), founder of the New York Urology Trade Association (representing the business interests of urology group practices in the State of New York), past Chairman of Access to Integrated Cancer Care (an informal advocacy group representing the rights of patients to access integrated services of the highest quality), is a member of the Board of Directors of Allied Urological Services, (the largest lithotripsy partnership in the United States , where he also functions as Chairman of the Finance Committee) and is Founder and Past-President of the Integrated Medical Foundation. Dr. Kapoor is a Fellow of the American College of Physician Executives.

Dr. Kapoor has published and lectured extensively on both clinical and business medical issues, and serves on a number of medical advisory boards, including the New York State Governor´s Prostate Cancer Advisory Panel. He is the recipient of the American Urological Association’s 2011 Ambrose-Reed Socioeconomic Essay Award, and continues to enjoy an active clinical practice along with his administrative duties.